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Patients with chronic critical limb ischemia,
defined as persistent ischemic rest pain or tissue loss
that necessitate analgesics and a severely reduced
peripheral blood pressure,1 have a high risk of ampu-
tation within 1 year (22%).2 The treatment of choice
is vascular reconstruction, percutaneous angioplasty,
or both. However, a considerable number of
patients (40%) remains in whom vascular recon-
struction is not performed.1 These patients general-
ly undergo treatment by means of medical treatment
(analgesics, anticoagulants, and vasoactive drugs)
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Purpose: Patients with non-reconstructable critical limb ischemia generally undergo med-
ical treatment only to prevent or postpone amputation. There is some evidence that
spinal cord stimulation (SCS) stimulates ischemic wound healing. Thus, this could ben-
efit limb survival through improved skin perfusion. We investigated the effect of SCS
versus conservative treatment on skin microcirculation in relation to treatment outcome
in patients with non-reconstructable critical limb ischemia.
Methods: Standard medical treatment plus SCS was compared with only standard med-
ical treatment in a multicenter randomized controlled trial comprised of 120 patients
with surgically non-reconstructable chronic rest pain or ulceration. We investigated skin
microcirculation by means of capillary microscopy, laser Doppler perfusion, and tran-
scutaneous oxygen measurements in the foot. The microcirculatory status just before
treatment was classified in three categories (poor, intermediate, and good) and was relat-
ed to limb survival after a minimum follow-up period of 18 months.
Results: Clinical parameters, peripheral blood pressures, and limb survival rates showed
no significant differences between the SCS and standard groups during the follow-up
period. In both treatment groups, amputation frequency after 18 months was high in
patients with an initially poor microcirculatory skin perfusion (SCS 80% vs standard
treatment 71%; NS) and low in those with a good skin perfusion (29% vs 11 %, respec-
tively; NS). In patients with an intermediate skin microcirculation amputation, frequen-
cy was twice as low in patients additionally treated with SCS as in the standard treat-
ment group (48% vs 24%; P = .08). In these patients, microcirculatory reactive hyper-
emia during the follow-up period reduced in the standard group but not in the SCS
group (P < .01).
Conclusion: Selection on the basis of the initial microcirculatory skin perfusion identifies
patients in whom SCS can improve local skin perfusion and limb survival. (J Vasc Surg
1999;30:236-44.)
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and local wound care or by means of primary ampu-
tation. Epidural spinal cord stimulation (SCS) has
been proposed in the literature as an alternative
treatment.3 This technique consists of a subcuta-
neously implanted neurostimulator that stimulates
the lower thoracic spinal cord via an electrode placed
in the epidural space, evoking paresthesias in the
area of pain. This technique has been accepted in the
treatment of some chronic pain syndromes and may
improve limb survival and healing of ischemic
ulcers.4,5 The basis of limb salvage and ulcer healing
may be correlated to the observation in a pilot study
that skin capillary perfusion improves in patients
with critical limb ischemia after SCS treatment.6
Although this technique is applied increasingly in
the treatment of peripheral vascular disease,6-10
nearly all studies so far lack adequate control groups,
which illustrates the need for randomized controlled
trials.11,12 To date, only one randomized controlled
study has been published, showing a statistically
non-significant difference in 18-month limb survival
of 62% versus 45% in favor of SCS.13 No controlled
studies have been performed so far that investigate
the effect of SCS on skin microcirculation.
To assess the potential effect of SCS in patients
with critical non-reconstructable leg ischemia, a
multicenter randomized controlled study supported
by the Dutch Health Care Council was performed in
the Netherlands. This study compared standard
treatment plus SCS with standard treatment only.
The outcome measures were limb salvage, quality of
life, and cost effectiveness. The results of this study
were published separately.14 Part of the protocol was
the investigation of the effect of both treatment
methods on skin microcirculation. This was based
on the allegedly positive effect of SCS on ischemic
ulcer healing,4,5 indicating that improved skin nutri-
tive blood flow may be the mechanism underlying
the potential beneficial effects of SCS. The aim of
this study was to evaluate the effect of standard and
SCS treatment on skin microcirculation and the
effects of the initial microcirculatory status on treat-
ment outcome.
METHODS
Patient population
The randomized controlled clinical study was
approved by the medical ethical committees of all 17
contributing hospitals in the Netherlands. The
patients were randomized via an independent ran-
domization center. Stratification was performed for
diabetes, ankle blood pressure, and the participating
center. The patients were included if:
1. They suffered clinically from critical limb
ischemia (ie, Fontaine15 stages III [rest pain] or
IV [ulceration or gangrene]).
2. Peripheral blood pressures met the criteria in the
European consensus document on chronic criti-
cal leg ischemia.1
3. Vascular reconstruction was not considered
because of non-reconstructability.
Non-reconstructability was defined as the absence
of a suitable autologous vein for distal bypass grafting
surgery or the absence of all three crural arteries on a
selective angiogram, which was a prerequisite for judg-
ment of the calf and foot arteries. It should delineate
Table I. Inclusion and exclusion criteria
Inclusion criteria
Chronic critical ischemia of one of the lower limbs in patients in whom a meaningful vascular reconstructive procedure is not 
considered:
Persistent rest pain for at least 2 weeks, undergoing treatment with analgesics, or ulceration or gangrene of foot or toes.
Doppler ankle systolic pressure ≤50 mm Hg or ankle/brachial pressure index ≤35%. For patients with diabetes mellitus and 
incompressible ankle arteries, absence of arterial ankle pulsations with physical examination.
Patient’s written informed consent.
Exclusion criteria
Vascular disorders other than atherosclerotic disease.
No rest pain (eg, only intermittent claudication) and no gangrene or ulceration.
Ulceration deeper than the fascia or with a largest diameter of >3 cm.
Intractable infection of ulceration or gangrene.
Bilateral critical ischemia.
Neoplastic or other concomitant disease restricting life expectancy to <l year.
Presence of a cardiac pacemaker.
Impossibility to implant an epidural electrode and stimulator.
Psychosocial incompetence of the patient to satisfy the follow-up schedule.
contrast down to the distal foot to assess a possible
recipient artery. The adequacy of the angiogram was
validated by an independent vascular surgeon. Venous
mapping was performed by means of routine duplex
scanning. Superficial femoral veins were not used. The
inclusion and exclusion criteria are summarized in
Table I. Further details are described elsewhere.14
Treatment
Treatment consisted of either optimal medical
treatment, including analgesics, anticoagulants,
vasoactive agents, local wound care, and antibiotics
if indicated (standard treatment), or SCS plus stan-
dard treatment. Standard treatment was identical in
both groups. The neurostimulator and lead pulse
generator with quadripolar electrode (Itrel II,
Medtronic, Minn) were implanted in one session.
The surgical procedure of the SCS implantation has
been described in detail elsewhere.6
Follow-up examination
Follow-up examination, including clinical exam-
ination, Doppler scan peripheral blood pressure, and
microcirculatory measurements, was performed 1,
3, 6, 12, and 18 months after randomization and at
the end of the trial. This period was considered ade-
quate, given the high incidence of amputation and
death.1 The patients who underwent SCS were
checked regularly to ensure that the paresthesias
were of sufficient amplitude and were experienced in
the painful ischemic area. Complications leading to
inadequate stimulation or removal of the system
implied that the patient underwent only standard
treatment but remained in the SCS group according
to the intention-to-treat principle. The endpoint of
the study was a major amputation of the limb (ie, of
the foot or higher).
Microcirculatory investigations
The non-invasive skin microcirculatory investiga-
tions (capillary microscopy, transcutaneous oxygen
pressure, and laser Doppler perfusion measure-
ments) were performed by a single, experienced
investigator with mobile equipment in a minivan,
which allowed the use of the same equipment in
each center.
Capillary microscopy. Capillary microscopy
enables the visualization of the nailfold capillaries of
the big toe in the sitting position and provides infor-
mation about capillary morphology (diameter, in
meters; density, in number per square millimeter of
nail fold skin) and erythrocyte velocity at rest (restv, in
micrometers per second) and during reactive hyper-
emia (peakv, in micrometers per second) after a stan-
dard period of arterial occlusion (1 minute) by inflat-
ing a cuff around the ankle. The time to reach peakv
(in seconds) was assessed as well. This technique
yields information exclusively about skin nutritive
flow. Images were recorded on videotape for off-fine
analysis.
Transcutaneous oxygen pressure. Transcu-
taneous oxygen pressure measurements enable the
assessment of skin oxygen supply by the superficial
vessels. Measurements were performed on the dor-
sum of the foot, with an electrode temperature of
44°C, at rest (restpO2, in millimeters of mercury)
and after a 3-minute arterial occlusion (peakpO2, in
millimeters of mercury). This enabled measurement
of the rate at which restpO2 is restored (reoxygena-
tion rate, in millimeters of mercury per second) and
of the time to reach 50% (in seconds) of restpO2 or
100% (in seconds) of the peakpO2.
Laser Doppler perfusion. Laser Doppler per-
fusion (LDP) measurements on the pulp of the great
toe provide information about total skin perfusion
(ie, flow in capillaries and deeper vessels), including
the arteriolovenular anastomoses that are mainly
involved in thermoregulation. The reactive hyper-
emia response after a 3-minute arterial occlusion was
measured as well (peak LDP minus rest LDP, in
arbitrary units) to assess the reserve capacity of skin
blood supply because the variability of LDP under
resting conditions is known to be great. Also, time
to 50% of rest LDP or 100% of peak LDP (in sec-
onds) and the reperfusion rate (to recover rest 
LDP, in arbitrary units per second) were assessed.
Transcutaneous oxygen pressure and LDP were per-
formed while the patient was in the supine position,
which improves discriminative power.16 In case the
patient had undergone a minor amputation (toe,
forefoot), measurements were performed just proxi-
mal to the amputation level. For further details con-
cerning the techniques used, a previous publication
can be referenced.16
Microcirculatory data analysis was performed at
least 6 months after each visit to avoid knowledge of
the patient’s identity and clinical status and recogni-
tion of the recordings. The microcirculatory status
of the patient’s ischemic foot was classified into
three categories according to the microcirculatory
findings at the first visit just before the start of any
treatment. These categories (ie, patients with a poor,
an intermediate, and a good microcirculatory perfu-
sion) were defined on the basis of microcirculatory
criteria to detect critical ischemia, as assessed in pre-
vious studies.16,17 The criteria for this categorization
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are shown in Table II. The treating physician was
kept unaware of the microcirculatory results.
Statistical analysis
The study had an 80% power to detect a hazard
ratio of 1.8 on the basis of a sample size of 60 in each
treatment group at an a level of .05, given an estimat-
ed overall amputation frequency of 60% and a mean
limb survival in the SCS-treated group of 6 months
and in the standard treatment group of 3 months.
Limb survival analysis was performed with the Kaplan-
Meier method for all strata and for each microcircula-
tory category separately. Statistical significance of the
differences between the strata was assessed with the
Wilcoxon rank sum test adapted for censored data
because the hazards in both treatment groups may
have been non-proportional. The effect of treatment
on microcirculatory parameters over time was evaluat-
ed with general estimating equation methods for
repeated measurements.18 Analysis was performed
with both the intention-to-treat and the per-protocol
principle. Missing values as the result of death or
amputation were treated with the “last-observation-
carried-forward” approach. Interaction terms between
the microcirculatory categories and treatment were
introduced to evaluate differential therapy effects
between the microcirculatory categories. The c 2 test
for trends was used to assess the treatment effect on
the microcirculatory status after 1 month. For this pur-
pose, the patients who underwent an amputation in
the first month were not discarded but were assumed
to have a poor microcirculation just before amputa-
tion. This was taken for the evaluation at 1 month.
RESULTS
Patient population
From November 1991 to May 1994, 120
patients with non-reconstructable chronic critical
limb ischemia consented to participate in the study.
Of these patients, only 111 were available for micro-
circulatory analysis because seven patients were ran-
domized and underwent treatment before the first
microcirculatory investigation could take place and
two were excluded because of protocol violation
(too large an ulcer, therapy refusal after randomiza-
tion). Patient intake data are presented in Table III.
There were no significant differences in these data
between both treatment groups. Also, cerebrovascu-
lar ischemic events (standard 53% vs SCS 48%),
smoking (44% vs 30%), and number of previous vas-
cular interventions (82% vs 73% undergoing one or
more than one intervention) were comparable.
Table II. Microcirculatory categories of skin perfusion
Poor
When complying to the criteria of all three techniques:
Capillary microscopy
Low capillary density (density, <20/mm2),17 or:
Low peak erythrocyte velocity (peakv, <50 m m/s),16 or:
No reactive hyperemia (peakv – restv, ≤0 m m/s)17
Transcutaneous pO2
Poor skin oxygenation (restpO2 and peakpO2, <10 mm Hg)
Laser Doppler scan perfusion
No reactive hyperemic response (peak – rest LDP, ≤3 AU)16
Intermediate
When the criteria of the other two categories were not met, ie:
RestpO2 or peakpO2 between 10 and 30 mm Hg, or:
Results of the different techniques fit into different categories
Good
When complying to the criteria of all three techniques:
Capillary microscopy
Normal capillary density (density, ‡ 20/mm2),17 and
Present reactive hyperemia (peakv – restv, >0 m m/s)17 and
Normal peak erythrocyte velocity (peakv, ‡ 50 m m/s)16
Trancutaneous pO2
Good skin oxygenation (restpO2 and peakpO2, ‡ 30 mm Hg)16
Laser Doppler scan perfusion
Present reactive hyperemic response (peak – rest LDP, >3 AU)16
peakv, Peak velocity; restv, velocity at rest; pO2, oxygen pressure; LDP, laser Doppler perfusion; AU, arbitary unit.
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Treatment and follow-up examination
Fifty-five patients were allocated to the stan-
dard treatment, and 56 were allocated to the SCS
treatment group. Complications of SCS treatment
were dislocation of the lead (n = 13), implantation
difficulties (n = 6), infection (n = 3), and an empty
battery (n = 3). In nine patients, the electrode was
removed during the follow-up period. In six
patients (10%), the electrode was removed because
SCS did not function at all or because the leads
could not be implanted. In the remaining three
patients, the electrode was removed because of a
major amputation. The number of patients in the
SCS group with analgesics (paracetamol, non-
steroidal anti-inflammatory drugs, or morphine
derivatives) was significantly lower than in the
standard group after 1, 3, and 6 months, as quan-
tified by means of the Medication Quantification
Scale.19 Cumulative patient survival in both
groups was comparable: 83% after 18 months in
both groups, and 62% (standard) versus 64%
(SCS) after 2 years. The percentage of patients
censored because of death was similar in both
groups: 18% versus 25%, respectively. Cumulative
limb survival was 68% versus 66% after 6 months,
46% (standard) versus 60% after 1 year, and 46%
versus 52% after 2 years for the standard and SCS
treatment, respectively (Fig 1). Because of the
lower amputation frequency, the post hoc power
of the study was reduced. Consequently, the
Wilcoxon test showed no significant differences
between the two groups (P = .47).
Fig 1. Overall cumulative limb survival rates (with Kaplan-Meier method) of patients who
undergo standard treatment and those who undergo additional spinal cord stimulation (SCS).
Numbers indicate patients at risk at different follow-up moments.
Table III. Patient intake data
Standard treatment SCS treatment
No. of patients 55 56
Sex (M/F) 33/22 32/24
Diabetes 20 23
Fontaine stage (III/IV) 20/35 22/34
Age (years)* 72 (38 to 93) 74 (41 to 89)
Ankle pressure (mm Hg)* 45 (0 to 96) 35 (0 to 70)
Ankle/brachial index (%)* 30 (20 to 35) 25 (0 to 63)
SCS, Spinal cord stimulation.
*Shown as median values and ranges.
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Microcirculatory investigations
Skin microcirculation could be investigated in all
patients at each follow-up examination until they
died, they underwent major amputation, or the
study was ended. Capillary microscopy was not pos-
sible in 18 patients (16%) because of amputation or
ulceration of the big toe. In these patients, LDP and
pO2 measurements were performed only. The medi-
an values at baseline and during the follow-up peri-
od of the parameters used to classify the patients in
both treatment groups are shown in Table IV, in
which the last observations of patients who under-
went amputation were carried forward. With gener-
al equation estimation, evaluation of the effect of
time on skin microcirculation showed a significant
improvement of peakv-restv (P < .01), restpO2 (P <
.05), and time to 50% pO2 (P < .05) during follow-
up examination, irrespective of treatment. No signif-
icant effect of treatment was found over all micro-
circulatory categories. When interaction terms were
introduced for initial microcirculatory classification,
a statistically significant treatment effect (P < .0l) was
apparent in the intermediate category for the para-
meters concerning the reactive hyperemia response
(peakv-restv and peak-rest LDP), which deteriorated
in the standard treatment group but not in the 
SCS group.
Intention to treat. Subdivision of the patients
according to their microcirculatory categorization
before treatment showed that the amputation rate
after 18 months was high (75%) in patients with a
poor initial microcirculatory status (Table V). In this
category, amputation rate and limb survival rate did
not differ between the SCS and the standard treat-
ment groups (P = .82). In the good category, the
amputation rate was low (19%) and, thus, limb sur-
vival rate was high, but not significantly different
between the treatment groups (P = .44). In contrast,
in the intermediate category, which comprised most
of the patients (n = 63), major amputation frequen-
cy after 12 and 18 months in the SCS group (24%)
was twice as low as in the standard treatment group
(48%). The cumulative limb survival curve for the
intermediate category is shown in Fig 2. In the
intermediate category, limb survival rate tended to
be better in the SCS than in the standard group (P
Fig 2. Cumulative limb survival rates (with Kaplan-Meier method) of patients in intermedi-
ate microcirculatory category who undergo standard treatment or additional spinal cord stim-
ulation (SCS). Numbers indicate patients at risk at different follow-up moments.
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= .17). A significantly different effect of the treat-
ment in these categories could not be found (P =
.20). The short-term effect of treatment on skin
microcirculation after 1 month showed no signifi-
cant effect in either treatment group.
Per protocol. The effects of a properly func-
tioning SCS (paresthesias in the painful area) on skin
microcirculation and limb survival was assessed by
means of a per-protocol analysis. For this purpose,
the periods from 0 to 1 month after randomization,
from 1 to 3 months, and from 3 months to end of
the follow-up period were considered as separate
observations in which SCS could be effective, so that
patients with effective paresthesias that occurred not
until after 1 or 3 months (eg, after repositioning of
the lead) could be included as well. Thus, 105
patients were available for analysis (Table V). Again,
amputation rate was high (75%) in the poor micro-
circulation group as opposed to a low rate (8%) in
the good microcirculation group, irrespective of the
therapy applied. In patients with an intermediate
skin microcirculation, amputation frequency, after
12 and 18 months in the standard treatment group,
was twice as high as compared with the SCS group.
Consequently, limb survival rate was higher in the
SCS group than in the standard treatment group,
but this difference did not reach the level of statisti-
cal significance (P = .08).
DISCUSSION
The overall effect of SCS on limb survival or skin
microcirculation was not significantly better than in
that of the standard conservative therapy. However,
when considering the status of skin microcirculation
Table IV. Microcirculatory results for each treatment group at baseline through 18 months (median values)
SCS Standard
Follow-up period (months) 0 1 3 6 12 18 0 1 3 6 12 18
Capillary microscopy
Density (n/mm2) 33 36 32 34 33 31 35 34 36 39 38 37
Peakv (m m/s) 63 63 64 55 63 60 75 70 61 45 52 63
Peakv – restv (m m/s) 2 12 8 5 12 12 2 2 1 2 1 1
Transcutaneous oximetry
RestpO2 (mm Hg) 10 13 11 17 18 17 10 8 4 9 9 8
PeakpO2 (mm Hg) 12 21 16 26 30 27 18 21 15 23 18 15
Laser Doppler perfusion
Peak LDP (AU) 9 13 20 21 30 30 10 18 24 28 32 46
Peak – rest LDP (AU) 3 4 2 2 5 6 3 4 3 5 4 5
SCS, Spinal cord stimulation; peakv, peak velocity; restv, velocity at rest; pO2, oxygen pressure; LDP, laser Doppler perfusion; AU, arbitary unit.
Table V. Amputation frequency in both treatment groups for each microcirculatory category
Microcirculatory No. of
6 months 12 months 18 months
assessment at baseline patients No. of patients % No. of patients % No. of patients % P value*
Intention to treat
Poor SCS 15 11 73 12 80 12 80 .69
Standard 17 9 53 12 71 12 71
Intermediate SCS 34 6 18 7 21 8 24 .17
Standard 29 6 21 14 48 14 48
Good SCS 7 1 14 1 14 2 29 .65
Standard 9 1 11 1 11 1 11
Per protocol
Poor SCS 15 11 73 12 80 12 80 .79
Standard 17 9 53 12 71 12 71
Intermediate SCS 31 5 16 6 19 7 23 .08
Standard 29 6 21 14 48 14 48
Good SCS 4 0 0 0 0 0 0 .56
Standard 9 1 11 1 11 1 11
SCS, Spinal cord stimulation.
*With Wilcoxon rank sum test.
in the ischemic area before treatment, patients with an
intermediate microcirculatory perfusion tended to
benefit from SCS, which deserves further investiga-
tion. Apparently, the ischemic legs of patients with
poor microcirculation are in a state that cannot be
reversed by any therapy; these patients may be better
off with primary amputation. Patients with a good
microcirculation have an advantageous natural course,
irrespective of the therapy. In these patients, SCS has
no specific advantage over other alternatives. Blood
pressure or clinical parameters were not able to dis-
cern patients who would benefit from a limb-saving
treatment. In contrast, microcirculatory investigations
could distinguish patients with a high risk for ampu-
tation. These techniques may therefore be a useful
additional technique to assess the severity and prog-
nosis of critical limb ischemia. Transcutaneous oxygen
measurements are easy to perform and could discern
between the three microcirculatory groups, with cut-
off values of 10 and 30 mm Hg. Thus, this technique
appeared to be the best stand-alone technique to
assess the severity of (critical) limb ischemia, and other
techniques may be more complicated and are not
readily available in most vascular laboratories. On the
other hand, capillary microscopy is the technique of
choice to appreciate nutritive skin perfusion and is
therefore particularly capable of judging its viabili-
ty.20,21 The high overall amputation frequency in the
first months illustrates the severity of the disease,
which may have been enhanced by the stringent
blood pressure inclusion criteria.
As to the possible working mechanism of SCS, the
beneficial effect on the reactive hyperemia response
and the trend of an increase in skin oxygen pressure,
combined with a more discrete effect on total skin
perfusion as measured by means of laser Doppler and
the absence of an effect on ankle blood pressure, sug-
gests a redistribution of flow towards particularly the
nutritive part of skin microcirculation rather than an
increase in total blood flow to the limb. This redistri-
bution may be the result of the suppression of pain
stimuli, which thereby lowers the sympathetic tone of
the arterioles and precapillary vessels of the skin, and,
thus, a better use of skin reserve capacity. The relief of
pain was more obvious in the SCS group than in the
standard treatment group. So, patients with a margin-
al, intermediate microcirculatory perfusion may have
benefitted more from SCS in that their microcircula-
tion remained sufficient to avoid further tissue loss
and finally an amputation. A short-term effect of SCS
could not be detected, probably because of the high
amputation rate in the first months after the start of
the treatment. This early period included patients
who eventually underwent an amputation and who
had a poor microcirculation, which is reflected by the
finding that microcirculatory results after 1 month did
not differ much from those at the start.
In conclusion, SCS showed a possible beneficial
effect only in a subgroup of patients with chronic crit-
ical limb ischemia, which deserves further study. Skin
microcirculatory investigation is a useful aid in the
prediction of an imminent amputation. The subgroup
that might profit from SCS had an intermediate skin
microcirculatory perfusion and an amputation fre-
quency half as high as in the standard group after 12
months. This suggests that, for the future application
and chances of success of this treatment method,
microcirculatory investigations are worthwhile to
screen the suitability of the patients and the effective-
ness of the treatment. A prospective randomized
study is needed to prove this possible profitable effect
in a group of patients with chronic critical limb
ischemia, selected on the basis of their skin microcir-
culation in centers that are familiar with SCS and
microcirculatory investigation.
We thank Medtronic Inc for sponsoring the microcir-
culatory equipment used in this study.
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APPENDIX
The contributors to the Dutch Spinal Cord
Stimulation trial were as follows:
Academic Hospital, Groningen: J.J.A.M. van der
Dungen, M.J. Staal.
Academic Hospital, Maastricht: P.J.E.H.M.
Kitslaar, M. van Kleef.
Academic Hospital Dijkzigt, Rotterdam: H. van
Urk, H.M. Klomp, N.A.J.J. Du Bois, E. Steyerberg,
D. Habbema, K. Lubsen.
Academic Medical Center, Amsterdam: M.J.H.M.
Jacobs, D.Th. Ubbink.
Catharina Hospital, Eindhoven: J. Buth, P.J.G.
de Gier.
Deventer Hospital, Deventer: D. van Lent.
De Weezenlanden Hospital, Zwolle: E.A. Kole,
F.J.N.A. Simons.
De Wever Hospital, Heerlen: H.P.J.K.M. van
Houtte, E.C.M. Bollen.
General Hospital N.-W. Veluwe, Harderwijk:
A.C. van der Ham.
Leyenburg Hospital, The Hague: J.C. Sier, N.
Lambooy.
Lievensberg Hospital, Bergen op Zoom: T.H.A.
Bikkers.
Maasland Hospital, Sittard: A.G.M. Hoofwijk.
Medical Center Alkmaar: H.A. van Dijk, P.J.
Thevenet.
Medical Spectrum Twente, Enschede: R.J. van
Det.
St. Antonius Hospital, Nieuwegein: F.L. Moll.
St. Clara Hospital, Rotterdam: T.I. Yo, G.
Kazemier.
St. Fransiscus Hospital, Rotterdam: C.H.A.
Wittens.
